Mozobil (Plerixafor)

Plerixafor, the active ingredient in Mozobil, is a CXCR4 antagonist presented as a 0.24 mg/mL injection solution for subcutaneous use. It mobilizes hematopoietic stem cells for autologous transplantation in patients with non‑Hodgkin lymphoma and multiple myeloma. The drug is indicated for mobilizing hematopoietic stem cells in preparation for autologous stem cell transplantation.

GNH USA supplies Mozobil as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Mozobil (plerixafor) is used to mobilize hematopoietic stem cells in hematologic malignancies. - Non‑Hodgkin lymphoma: mobilizes stem cells for autologous transplantation. - Multiple myeloma: mobilizes stem cells for autologous transplantation. - Other eligible hematologic cancers: facilitates collection of peripheral blood stem cells for autologous transplant.

Plerixafor may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Injection site pain: mild discomfort at the subcutaneous injection site. - Nausea: transient feeling of sickness. - Diarrhea: loose stools. - Fatigue: general tiredness. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, urticaria, or anaphylaxis. - Splenic rupture: rare but potentially life‑threatening. - Severe leukocytosis: markedly elevated white blood cell count. - Thromboembolic events: blood clots in veins or arteries.

When using Mozobil, several precautions should be observed to ensure patient safety and product integrity. - Patient assessment: evaluate hematologic status and eligibility for stem cell mobilization. - Concomitant G‑CSF: coordinate timing with granulocyte‑colony stimulating factor as recommended. - Monitoring: observe for signs of hypersensitivity and injection‑site reactions during and after administration. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks, as safety data are limited. - Renal function: adjust use in patients with impaired renal clearance, following clinical guidance. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Plerixafor can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Concurrent use with strong CYP3A4 inhibitors: may increase systemic exposure; caution advised. - Live vaccines: immunosuppression from stem cell mobilization may reduce vaccine efficacy; avoid concurrent administration.

Moderate Interactions (Monitor Closely): - G‑CSF agents: additive effect on stem cell mobilization; dosing schedule should be coordinated. - Anticoagulants: monitor for bleeding risk if splenic rupture occurs. - Diuretics: assess fluid balance as plerixafor may cause transient shifts.